GLP-1 trial evidence explained
The SURMOUNT, STEP, SELECT, OASIS and ATTAIN trials in plain English: who took part, what was measured and what the results mean.
SURMOUNT-1 explained: tirzepatide for obesity
SURMOUNT-1 in plain English: who took part, the 72-week tirzepatide weight results at each dose and what the trial cannot tell you.
3 min readEvidenceSTEP 1 explained: semaglutide 2.4 mg and weight loss
STEP 1 in plain English: the 68-week Wegovy injection trial in adults without diabetes, its main result and how to read the percentages.
3 min readEvidenceSELECT explained: semaglutide and cardiovascular events
SELECT in plain English: who took part, the cardiovascular endpoint, relative and absolute risk results and what they mean for UK Wegovy use.
3 min readEvidenceOASIS 4 explained: oral semaglutide 25 mg for weight loss
OASIS 4 in plain English: the Wegovy tablet trial, its 64-week weight result and why the figures do not compare directly with injections or Foundayo.
3 min readEvidenceATTAIN-1 explained: orforglipron and the Foundayo evidence
ATTAIN-1 in plain English: the 72-week orforglipron trial behind Foundayo, its dose results and why cross-trial comparisons mislead.
3 min readEvidenceSURMOUNT-5 explained: tirzepatide vs semaglutide
SURMOUNT-5 in plain English: the head-to-head tirzepatide and semaglutide obesity trial, the doses tested and what it says about newer Wegovy forms.
3 min read